Yilmaz B.Kelekci S.Ertas I.E.Ozel M.Sut N.Mollamahmutoglu L.Danisman N.2024-06-122024-06-1220070932-0067https://doi.org/10.1007/s00404-007-0374-9https://hdl.handle.net/20.500.14551/16108Objective: The aim of this randomized prospective study was to compare efficacy and side effects of saline moistened misoprostol with dry misoprostol, administered 800 ?g intravaginally every 6 h up to a maximum of 3 doses in 24 h for second trimester pregnancy termination. Materials and methods: A total of 81 women seeking termination of second trimester pregnancy (55 fetal death, 17 fetal structural anomaly, 5 chromosomal abnormality, 4 other reasons) were randomly assigned to one of two treatment groups: (1) intravaginal non-moistened (dry) misoprostol in group A (n = 40) or (2) misoprostol moistened with 3 ml of saline in group B (n = 41). Results: All of the patients in either group aborted within 48 h (100% success rate). Delivery was achieved in a median (interquartile range) of 13 (40) h with the group A protocol and 12 (36) h with the group B protocol (P = 0.652). Delivery with first dose, delivery within 12 h and delivery within 24 h were similar (P > 0.05) in group B (34.1, 87.5 and 60%, respectively) and group A (25, 82.9, 46.3, respectively). Both treatment regimens were tolerable and with similar side effects. Conclusion: Misoprostol moistened with saline was not more effective than dry misoprostol for second trimester pregnancy termination. © 2007 Springer-Verlag.en10.1007/s00404-007-0374-9info:eu-repo/semantics/closedAccessDry; Misoprostol; Moistened; Saline; Second Trimester Pregnancy TerminationMisoprostol; Sodium Chloride; Adult; Article; Chill; Chromosome Aberration; Clinical Trial; Comparative Study; Controlled Clinical Trial; Controlled Study; Diarrhea; Drug Effect; Drug Efficacy; Female; Fetus Death; Human; Major Clinical Study; Nausea; Pregnancy Termination; Prospective Study; Randomized Controlled Trial; Second Trimester Pregnancy; Vomiting; Abortifacient Agents; Abortion, Therapeutic; Administration, Intravaginal; Adult; Female; Humans; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Prospective Studies; Sodium Chloride; Treatment OutcomeArticle27655115162-s2.0-3454866221817453221Q2